https://www.selleckchem.com/btk.html
High compliance in young ASA3 patients with liver colorectal metastases was associated with an increase of 481 days of DFS. ERAS compliance ≥ 67% tends to be associated with a reduction in the delay to adjuvant chemotherapy for young patients with hepatobiliary and pancreatic malignancies. More prospective studies with strict adhesion to the ERAS protocol are needed to confirm these results. ERAS compliance ≥ 67% tends to be associated with a reduction in the delay to adjuvant chemotherapy for young patients with hepatobiliary and pancreatic maligna
Like
Comment
Share
